Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer

被引:34
作者
Bauer, Callie M. Cox [1 ]
Greer, Danielle M. [2 ]
Kram, Jessica J. F. [2 ]
Kamelle, Scott A. [3 ]
机构
[1] Aurora Hlth Care, Aurora Sinai Med Ctr, Dept Obstet & Gynecol, Milwaukee, WI USA
[2] Aurora Hlth Care, Aurora Sinai Med Ctr, Ctr Urban Populat, Aurora UW Med Grp, Milwaukee, WI USA
[3] Aurora Hlth Care, Aurora St Lukes Med Ctr, Dept Oncol, Milwaukee, WI USA
关键词
Endometrial cancer; Endometrioid; Lymphatic dissemination; Myometrial invasion; Nodal metastatic disease; Tumor cell grade; Tumor diameter; NODAL METASTASIS; RISK; LYMPHADENECTOMY; CARCINOMA; INVASION; TRIAL; SIZE; MRI;
D O I
10.1016/j.ygyno.2016.02.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. To assess the utility of tumor diameter (TD) for predicting lymphatic dissemination (LD) and determining need for lymphadenectomy following diagnosis of endometrioid endometrial cancer. Methods. Patients diagnosed with stage I-III endometrioid endometrial cancer during 2003-2013 who underwent complete lymphadenectomy during hysterectomy were studied. Intraoperative predictors of LD included TD, grade, myometrial invasion (MI), age, body mass index, and race/ethnicity. Candidate logistic regression models of LD were evaluated for model fit and predictive power. Results. Of 737 cancer patients, 68 (9.2%) were node-positive. Single-variable models with only continuous TD (c-statistic 0.77, 95% CI 0.71-0.83) and dichotomous TD with 50-mm cut-off (TD50; c-statistic 0.73, 95% CI 0.67-0.78) were significantly more predictive than with the standard 20-mm cut-off (c-statistic 0.56, 95% CI 0.53-0.59). Overall, the most important LD predictors were TD50 and MI3rds (three-category form). The best candidate model (c-statistic 0.84, 95% CI 0.80-0.88) suggested odds of LD were five times greater for TD >50 mm than <= 50 mm (OR 4.91, 95% CI 2.73-8.82) and six and ten times greater for MI >33% to <= 66% (OR, 5.70; 95% CI, 2.25-14.5) and >66% (OR 10.2, 95% CI 4.11-25.4), respectively, than <= 33%. Best-model false-negative (0%) and positive (57.2%) rates demonstrated marked improvement over traditional risk-stratification false-negative (1.5%) and positive (762%) rates (c-statistic 0.77, 95% CI 0.72-0.82). Conclusions. Tumor diameter is an important predictor of LD. Our risk model, containing modified forms of MI and TD, yielded a lower false-negative rate and can significantly decrease the number of lymphadenectomies performed on low-risk women. Published by Elsevier Inc.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 26 条
[2]   The use of MRI for selecting patients with endometrial cancer and significant co-morbidities for vaginal hysterectomy [J].
Abu Freij, Mazen ;
Saleh, Hanan ;
Rawlins, Hannah ;
Duncan, Tim ;
Nieto, Jo .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 283 (05) :1097-1101
[3]  
[Anonymous], 2009, Obstet Gynecol, V114, P1156, DOI 10.1097/AOG.0b013e3181c33c72
[4]  
[Anonymous], AM J OBSTET GYNECOL
[5]   Vaginal versus abdominal hysterectomy in endometrial cancer: a retrospective study in a selective population [J].
Berretta, R. ;
Merisio, C. ;
Melpignano, M. ;
Rolla, M. ;
Ceccaroni, M. ;
De Ioris, A. ;
Patrelli, T. S. ;
Nardelli, G. B. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) :797-802
[6]   Assessment of tumor size as a useful marker for the surgical staging of endometrial cancer [J].
Berretta, Roberto ;
Patrelli, Tito Silvio ;
Migliavacca, Costanza ;
Rolla, Martino ;
Franchi, Laura ;
Monica, Michela ;
Modena, Alberto Bacchi ;
Gizzo, Salvatore .
ONCOLOGY REPORTS, 2014, 31 (05) :2407-2412
[7]   Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: Current evidence [J].
Bogani, Giorgio ;
Dowdy, Sean C. ;
Cliby, William A. ;
Ghezzi, Fabio ;
Rossetti, Diego ;
Mariani, Andrea .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2014, 40 (02) :301-311
[8]   Carcinoma of the corpus uteri [J].
Creasman, W. T. ;
Odicino, F. ;
Maisonneuve, P. ;
Quinn, M. A. ;
Beller, U. ;
Benedet, J. L. ;
Heintz, A. P. M. ;
Ngan, H. Y. S. ;
Pecorelli, S. .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 95 :S105-S143
[9]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[10]  
2-8